Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

PubWeight™: 5.64‹?› | Rank: Top 1%

🔗 View Article (PMID 14605050)

Published in Chest on November 01, 2003

Authors

Richard G Wunderink1, Jordi Rello, Sue K Cammarata, Rodney V Croos-Dabrera, Marin H Kollef

Author Affiliations

1: Methodist Healthcare Memphis and the University of Tennessee,Memphis, TN 38104-3499, USA. WunderiR@methodisthealth.org

Articles citing this

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20

Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev (2015) 1.94

Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol (2006) 1.81

Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest (2010) 1.76

Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol (2008) 1.68

Nosocomial pneumonia: therapy is just not good enough. Chest (2003) 1.39

Methicillin-resistant Staphylococcus aureus-induced thrombo-inflammatory response is reduced with timely antibiotic administration. Thromb Haemost (2013) 1.39

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother (2011) 1.25

New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis (2008) 1.21

Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VII--Guidelines for antibiotic administration in severely injured patients. J Trauma (2008) 1.21

Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. Clin Microbiol Rev (2007) 1.20

Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci (2010) 1.13

Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis (2007) 1.13

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother (2012) 1.12

Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother (2012) 1.09

Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin Immunopathol (2011) 1.06

Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother (2012) 1.05

Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis (2005) 1.04

A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis (2006) 1.01

Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis (2013) 1.01

Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol (2014) 1.00

Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open (2013) 0.99

Current and novel antibiotics against resistant Gram-positive bacteria. Infect Drug Resist (2008) 0.98

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest (2004) 0.97

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci. Antimicrob Agents Chemother (2007) 0.97

Ventilator associated pneumonia. Postgrad Med J (2006) 0.95

Bench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Crit Care (2004) 0.95

Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy. Eur J Med Res (2010) 0.94

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother (2012) 0.92

The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (2010) 0.91

Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur J Clin Microbiol Infect Dis (2011) 0.91

Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care (2014) 0.90

Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2008) 0.89

Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection. Eur J Clin Microbiol Infect Dis (2005) 0.88

[Diagnosis and therapy of sepsis]. Clin Res Cardiol (2006) 0.87

Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit. Crit Care (2009) 0.87

In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.87

Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol (2014) 0.87

Ventilator-associated pneumonia. Australas Med J (2014) 0.86

Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfection. PLoS One (2013) 0.85

Endemic linezolid-resistant Staphylococcus epidermidis in a critical care unit. Eur J Clin Microbiol Infect Dis (2008) 0.85

Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis (2010) 0.83

The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One (2013) 0.83

Capsaicin protects mice from community-associated methicillin-resistant Staphylococcus aureus pneumonia. PLoS One (2012) 0.83

Screening cardiac surgery patients for MRSA: an economic computer model. Am J Manag Care (2010) 0.83

Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest (2004) 0.83

Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant. Antimicrob Agents Chemother (2011) 0.83

FDA evaluation of antimicrobials: subgroup analysis. Chest (2005) 0.82

The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. Vaccine (2012) 0.82

Clinical response and hospital costs associated with the empirical use of vancomycin and linezolid for hospital-acquired pneumonia in a Chinese tertiary care hospital: a retrospective cohort study. Clinicoecon Outcomes Res (2014) 0.81

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis (2013) 0.81

High frequency of methicillin-resistant Staphylococcus aureus in Peshawar Region of Pakistan. Springerplus (2016) 0.80

Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 0.80

Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility? Antimicrob Agents Chemother (2005) 0.80

Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia. Pak J Med Sci (2013) 0.80

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). Ther Clin Risk Manag (2012) 0.79

Treatment of Gram-positive infections in critically ill patients. BMC Infect Dis (2014) 0.78

PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob Agents Chemother (2011) 0.78

Linezolid has unique immunomodulatory effects in post-influenza community acquired MRSA pneumonia. PLoS One (2015) 0.76

Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion. J Inflamm (Lond) (2010) 0.75

Community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia without evidence of antecedent viral upper respiratory infection. Can J Infect Dis Med Microbiol (2014) 0.75

Recombinant lysostaphin protects mice from methicillin-resistant Staphylococcus aureus pneumonia. Biomed Res Int (2014) 0.75

Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Crit Care (2014) 0.75

Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China. Clinicoecon Outcomes Res (2016) 0.75

A sentinel fatal paediatric case of community-associated methicillin-resistant Staphylococcus aureus in Canada. Paediatr Child Health (2007) 0.75

An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infect Drug Resist (2014) 0.75

Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts. Med Intensiva (2012) 0.75

Fatal persistent methicillin-resistant Staphylococcus aureus bacteremia and vascular graft infections complicated with the formation of multiple abscesses despite aggressive medical therapy. SAGE Open Med Case Rep (2015) 0.75

Articles by these authors

International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57

Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis (2012) 7.97

Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest (2002) 6.13

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother (2005) 5.35

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest (2006) 4.51

Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med (2006) 4.10

DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99

Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest (2002) 3.98

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis (2003) 3.93

Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis (2008) 3.88

Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis (2011) 3.78

The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs (2007) 3.63

Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med (2002) 3.63

A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother (2005) 3.49

Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med (2004) 3.49

Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care (2009) 3.48

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20

Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2008) 3.13

Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA (2012) 3.13

Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. Thorax (2013) 3.05

Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med (2007) 2.94

The importance of fluid management in acute lung injury secondary to septic shock. Chest (2009) 2.92

Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy. Crit Care Med (2015) 2.87

Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis. Crit Care Med (2015) 2.86

Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients*. Crit Care Med (2014) 2.86

Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med (2005) 2.70

Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med (2003) 2.59

Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest (2008) 2.57

Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med (2009) 2.57

Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis (2009) 2.54

Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med (2006) 2.51

Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother (2007) 2.49

Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med (2007) 2.44

Patients with New York Heart Association class III heart failure may benefit with high flow nasal cannula supportive therapy: high flow nasal cannula in heart failure. J Crit Care (2013) 2.43

Implementation of a real-time computerized sepsis alert in nonintensive care unit patients. Crit Care Med (2011) 2.35

Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest (2013) 2.32

Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest (2003) 2.31

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med (2004) 2.30

Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med (2010) 2.29

A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest (2004) 2.26

Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med (2007) 2.22

Endotracheal tube intraluminal volume loss among mechanically ventilated patients. Crit Care Med (2004) 2.20

Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med (2011) 2.16

Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med (2010) 2.15

Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. JPEN J Parenter Enteral Nutr (2002) 2.15

Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol (2004) 2.13

Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med (2003) 2.13

Pneumonia Pathogen Characterization Is an Independent Determinant of Hospital Readmission. Chest (2015) 2.09

Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. Chest (2009) 2.09

A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med (2007) 2.08

A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med (2012) 2.06

Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med (2008) 2.06

A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther (2007) 2.05

Attitudes of respiratory therapists and nurses about measures to prevent ventilator-associated pneumonia: a multicenter, cross-sectional survey study. Respir Care (2007) 2.03

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med (2003) 1.98

Acinetobacter baumannii: a threat for the ICU? Intensive Care Med (2003) 1.93

Delirium as detected by the CAM-ICU predicts restraint use among mechanically ventilated medical patients. Crit Care Med (2005) 1.92

Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis (2003) 1.90

Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med (2009) 1.89

Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med (2007) 1.88

A randomized trial of dental brushing for preventing ventilator-associated pneumonia. Chest (2009) 1.87

Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med (2006) 1.86

Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis (2004) 1.85

New issues and controversies in the prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med (2010) 1.84

A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria. Crit Care Med (2012) 1.82

Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest (2008) 1.81

Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents (2011) 1.80

Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med (2006) 1.80

Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med (2014) 1.77

Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med (2002) 1.72

Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med (2008) 1.72

Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med (2009) 1.71

Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia. Crit Care Med (2007) 1.66

Host adaptive immunity deficiency in severe pandemic influenza. Crit Care (2010) 1.64

Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest (2002) 1.63

Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care (2012) 1.62

Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol (2007) 1.61

Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia. Crit Care Med (2003) 1.61

Severe 2009 A/H1N1v influenza in pregnant women in Spain. Crit Care Med (2011) 1.61

Identifying critically ill patients at risk for inappropriate antibiotic therapy: a pilot study of a point-of-care decision support alert. Crit Care Med (2014) 1.60

Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med (2005) 1.60

Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitals. Clin Infect Dis (2013) 1.60

A prospective evaluation of ventilator-associated conditions and infection-related ventilator-associated conditions. Chest (2015) 1.59

Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med (2004) 1.58

Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med (2008) 1.58

Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit Care Med (2006) 1.57

Use of a handheld computer by respiratory care practitioners to improve the efficiency of weaning patients from mechanical ventilation. Crit Care Med (2002) 1.56

A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54

The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest (2007) 1.53

Patient safety event reporting in critical care: a study of three intensive care units. Crit Care Med (2007) 1.51

A randomized trial of conventional chest physical therapy versus high frequency chest wall compressions in intubated and non-intubated adults. Respir Care (2011) 1.51

Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med (2013) 1.50

Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med (2004) 1.49

Centers for Disease Control and Prevention guidelines for preventing central venous catheter-related infection: results of a knowledge test among 3405 European intensive care nurses. Crit Care Med (2009) 1.48

Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. Crit Care Med (2013) 1.48

Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest (2008) 1.47